Lee Michael S, Shlofmitz Evan, Lluri Gentian, Kong Jeremy, Neverova Natalya, Shlofmitz Richard
Division of Cardiology, UCLA Medical Center, Los Angeles, CA, USA.
Department of Cardiology, Northwell Health, Manhasset, NY, USA.
Cardiovasc Revasc Med. 2017 Oct-Nov;18(7):497-500. doi: 10.1016/j.carrev.2017.05.005. Epub 2017 May 7.
This study analyzed the outcomes of patients who presented with non-ST-elevation myocardial infarction (NSTEMI) and subsequently underwent orbital atherectomy for severe coronary artery calcification (CAC).
Patients who present with NSTEMI have increased risk for death and recurrent MI after percutaneous coronary intervention (PCI). Patients with severe CAC have worse outcomes after PCI.Orbital atherectomy modifies calcified plaque, facilitating stent delivery and optimizing stent expansion. There are no data on these patients who present with NSTEMI who undergo orbital atherectomy.
Of the 454 consecutive real-world patients who underwent orbital atherectomy in our retrospective multicenter registry, 51 patients (11.2%) presented with NSTEMI. The primary safety endpoint was the rate of major adverse cardiac and cerebrovascular events (MACCE) at 30days.
Patients with NSTEMI had a higher prevalence of chronic kidney disease, lower mean ejection fraction, and required more vessels to be treated. The primary endpoint was similar in patients who presented with and without NSTEMI (2.0% vs. 2.2%, p=0.9), as were the 30-day rates of death (2.0% vs. 1.2%, p=0.67), MI (0% vs. 1.2%, p=0.42), target vessel revascularization (0% vs. 0%, p>0.91), and stroke (0% vs. 0.2%, p=0.72). The rates of angiographic complications and stent thrombosis rate were low in both groups.
Despite having worse baseline characteristics, patients who presented with NSTEMI and subsequently underwent orbital atherectomy had similar clinical outcomes compared with patients without NSTEMI.
本研究分析了非ST段抬高型心肌梗死(NSTEMI)患者随后因严重冠状动脉钙化(CAC)接受眼眶旋磨术的结局。
NSTEMI患者经皮冠状动脉介入治疗(PCI)后死亡和再发心肌梗死的风险增加。严重CAC患者PCI后的结局较差。眼眶旋磨术可改善钙化斑块,便于支架置入并优化支架扩张。尚无关于这些NSTEMI患者接受眼眶旋磨术的数据。
在我们的回顾性多中心注册研究中,连续454例接受眼眶旋磨术的真实世界患者中,51例(11.2%)为NSTEMI患者。主要安全终点是30天时的主要不良心脑血管事件(MACCE)发生率。
NSTEMI患者慢性肾脏病患病率更高,平均射血分数更低,需要治疗的血管更多。有和没有NSTEMI的患者主要终点相似(2.0%对2.2%,p=0.9),30天死亡率(2.0%对1.2%,p=0.67)、心肌梗死发生率(0%对1.2%,p=0.42)、靶血管血运重建率(0%对0%,p>0.91)和卒中发生率(0%对0.2%,p=0.72)也相似。两组的血管造影并发症发生率和支架血栓形成率均较低。
尽管基线特征较差,但NSTEMI患者随后接受眼眶旋磨术与无NSTEMI患者的临床结局相似。